SecurityTGXSF / Tigenix Sa
InstitutionCormorant Asset Management, LLC
Shares9,972,386
Ownership 3.37%

Cormorant Asset Management, LLC discloses 3.37% passive ownership in TGXSF / Tigenix Sa

February 14, 2018 - Cormorant Asset Management, LLC has filed an SC 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 9,972,386 shares of Tigenix Sa (OTC:TGXSF). This represents 3.37 percent ownership of the company. In their previous filing dated February 14, 2017, Cormorant Asset Management, LLC had reported owning 14,472,631 shares, indicating a decrease of -31.09 percent.

13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File
Date
Effective
Date
Form Prev
Shares
Reported
Shares
Change in Shares
(Percent)
Ownership
(Percent)
Change in Ownership
(Percent)
2018-02-14 2018-02-14 SC 13G/A 14,472,631 9,972,386 -31.09 3.37 -42.20
2017-02-14 2017-02-14 SC 13G 12,150,794 14,472,631 19.11 5.83 19.22
2016-12-23 2016-12-23 SC 13G 14,601,663 5.88

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

13F Filings

The Security, Class, and CUSIP columns in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names and cusips.

In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Effective
Date
Form Security Class CUSIP Share
Price
Shares Change
(%)
Value
(x1000)
Change
(%)
Cost
(x1000)
Profit
(x1000)
Return
(%)
2017-06-30 13F-HR TIGENIX SPONSORED ADS 88675R109 0 -100.00 0 -100.00
2017-03-31 13F-HR TIGENIX SPONSORED ADS 88675R109 15.09 129,032 0.00 2,013 7.02 0 132 7.02
2016-12-31 13F-HR TIGENIX SPONSORED ADS 88675R109 129,032 1,881

Related SEC Filings

TGXSF / Tigenix Sa / Cormorant Asset Management, LLC - 3G/A (Passive Investment)

2018-02-16 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549       SCHEDULE 13G       Under the Securities Exchange Act of 1934       (Amendment No. 2)*     TiGenix NV     (Name of Issuer)     Ordinary Shares, no par value per share     (Title of Class of Securities)     88675R109     (CUSIP Number)     December 31, 2017     (Date of Event which Requires Filing of this Statement)   Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ ]           

TGXSF / Tigenix Sa / Cormorant Asset Management, LLC - 3G/A (Passive Investment)

2018-02-16 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549       SCHEDULE 13G       Under the Securities Exchange Act of 1934       (Amendment No. 2)*     TiGenix NV     (Name of Issuer)     Ordinary Shares, no par value per share     (Title of Class of Securities)     88675R109     (CUSIP Number)     December 31, 2017     (Date of Event which Requires Filing of this Statement)   Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ ]           

TGXSF / Tigenix Sa / TAKEDA PHARMACEUTICAL CO LTD - SC 13D (Activist Investment)

2018-01-12 sec.gov
SC 13D     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No.     )*     TiGenix (Name of Issuer) Ordinary shares, no nominal value (“Shares”) American Depositary Shares (“ADSs”), each representing 20 Shares (Title of Class of Securities) ISIN BE0003864817 (Shares) CUSIP 88675R109 (ADSs) (CUSIP Number) James Kehoe Takeda Pharmaceutical Company Limited 12-10, Nihonbashi 2-Chome, Chuo-ku, Tokyo 103-8668

TGXSF / Tigenix Sa / TAKEDA PHARMACEUTICAL CO LTD - SC 13D (Activist Investment)

2018-01-12 sec.gov
SC 13D     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No.     )*     TiGenix (Name of Issuer) Ordinary shares, no nominal value (“Shares”) American Depositary Shares (“ADSs”), each representing 20 Shares (Title of Class of Securities) ISIN BE0003864817 (Shares) CUSIP 88675R109 (ADSs) (CUSIP Number) James Kehoe Takeda Pharmaceutical Company Limited 12-10, Nihonbashi 2-Chome, Chuo-ku, Tokyo 103-8668

Tigenix SCHEDULE 13G (Passive Acquisition of More Than 5% of Shares)

2017-07-13 sec.gov
Schedule 13G     UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549     SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.    )*     TiGenix   (Name of Issuer)         ordinary shares, no nominal value per share         (Title of Class of Securities)                 88675R 10 9                 (CUSIP Number)                 December 20, 2016                 (Date of Event Which Requires Filing of this Statement)     Check the appropriate box to designate t

Related News Stories

CFRX / ContraFect Corporation - Stock Institutional Ownership and Shareholders - Fintel.io

2018-02-13 fintel.io
ContraFect Corporation (NASDAQ:CFRX) has 45 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 57,326,558 shares. Largest shareholders include Fosun Industrial Co., Ltd, Fosun International Ltd, Baker Brothers Advisors LP, Federated Investors Inc /pa/, Adage Capital Partners GP LLC, Cormorant Asset Management, LLC, Bvf Inc/il, 683 Capital Management, LLC, Oracle Investment Management Inc, and Alyeska Investment Group, L. (64-1)

GEMP / Gemphire Therapeutics Inc. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-02-13 fintel.io
Gemphire Therapeutics Inc. (NASDAQ:GEMP) has 33 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 3,840,029 shares. Largest shareholders include Excel Venture Fund II, L.P., Cormorant Asset Management, LLC, Adage Capital Partners GP LLC, Northpointe Capital Llc, Bamco Inc /ny/, Cambridge Investment Research Advisors, Inc. (8-0)

OVID / Ovid Therapeutics Inc. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-02-13 fintel.io
Ovid Therapeutics Inc. (NASDAQ:OVID) has 58 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 6,836,868 shares. Largest shareholders include FMR LLC / Fidelity, BlackRock Inc., Jennison Associates Llc, Redmile Group, LLC, Oppenheimer Funds Inc, Price T Rowe Associates Inc /md/, Baker Brothers Advisors LP, Ameriprise Financial Inc, Driehaus Capital Management Llc, and Cormorant Asset Management, LLC. (80-0)

CLSD / Clearside Biomedical, Inc. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-02-09 fintel.io
Clearside Biomedical, Inc. (NASDAQ:CLSD) has 62 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 14,099,324 shares. Largest shareholders include Wellington Management Group LLP, Cormorant Asset Management, LLC, RMI Investments S.a.r.l., BlackRock Inc., FMR LLC / Fidelity, Rock Springs Capital Management LP, Hillhouse Capital Management, Ltd. (33-0)

MRSN / Mersana Therapeutics, Inc. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-02-08 fintel.io
Mersana Therapeutics, Inc. (NASDAQ:MRSN) has 59 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 17,491,196 shares. Largest shareholders include NEA Management Company, LLC, Wellington Management Group Llp, FMR LLC / Fidelity, Rock Springs Capital Management LP, ProQuest Associates IV LLC, Rho Capital Partners Inc, Arrowpoint Asset Management, LLC, JP Morgan Chase & Co, Cormorant Asset Management, LLC, and BlackRock Inc. (32-0)

Bone Therapeutics: In (Re)Search For Money

2018-01-31 seekingalpha
On October 31, I released a focus article on Bone Therapeutics (OTC:BNZPF). On one hand, I was fairly excited about the crucial phase III interim results on osteonecrosis that are expected in H2 2018. On the other hand, I also warned investors on the less comfortable cash position of the company. In my previous estimates, I presumed a cash runway until May 2018. This article is intended to discuss recent developments concerning the company's cash position.

Takeda's Offer On Tigenix - Good Deal Or Not?

2018-01-12 seekingalpha
On the 5th of January, shareholders of TiGenix (NASDAQ:TIG) (OTC:TGXSF) were delighted with an unexpected treat. Japanese based medicine maker Takeda (OTCPK:TKPYY) (OTCPK:TKPHF) announced its intentions to acquire the Belgium-based biotech company. Takeda is offering €1.78 per share (~$2.14) - a premium of roughly 82% based on the last closing price of €0.98. This article intends to assess the bid.




CUSIP: 88675R109